Yonsei Med J.  2007 Oct;48(5):731-747. 10.3349/ymj.2007.48.5.731.

Peripartum Cardiomyopathy: Review of the Literature

• Bhakta P
• Biswas BK
• Banerjee B

• KMID: 1122609
• DOI: http://doi.org/10.3349/ymj.2007.48.5.731

Abstract

Peripartum cardiomyopathy (PPCM) is a rare but serious form of cardiac failure affecting women in the last months of pregnancy or early puerperium. Clinical presentation of PPCM is similar to that of systolic heart failure from any cause, and it can sometimes be complicated by a high incidence of thromboembolism. Prior to the availability of echocardiography, diagnosis was based only on clinical findings. Recently, inclusion of echocardiography has made diagnosis of PPCM easier and more accurate. Its etiopathogenesis is still poorly understood, but recent evidence supports inflammation, viral infection and autoimmunity as the leading causative hypotheses. Prompt recognition with institution of intensive treatment by a multidisciplinary team is a prerequisite for improved outcome. Conventional treatment consists of diuretics, beta blockers, vasodilators, and sometimes digoxin and anticoagulants, usually in combination. In resistant cases, newer therapeutic modalities such as immunomodulation, immunoglobulin and immunosuppression may be considered. Cardiac transplantation may be necessary in patients not responding to conventional and newer therapeutic strategies. The role of the anesthesiologist is important in perioperative and intensive care management. Prognosis is highly related to reversal of ventricular dysfunction. Compared to historically higher mortality rates, recent reports describe better outcome, probably because of advances in medical care. Based on current information, future pregnancy is usually not recommended in patients who fail to recover heart function. This article aims to provide a comprehensive updated review of PPCM covering etiopathogeneses, clinical presentation and diagnosis, as well as pharmacological, perioperative and intensive care management and prognosis, while stressing areas that require further research.

Keyword

Cardiomyopathy; peripartum; obstetrics; complications; anesthesia

MeSH Terms

Anesthesia, Obstetrical/adverse effects
Echocardiography, Doppler
Female
Heart Failure/*diagnosis/etiology/therapy
Humans
Incidence
Mortality
Pregnancy
Pregnancy Complications, Cardiovascular/*diagnosis/etiology/therapy
Prognosis
Recurrence
Risk Factors
Ventricular Dysfunction, Left/ultrasonography

Reference

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971. 44:964–968.

2. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971. 44:1053–1061.

3. Veille JC. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol. 1984. 148:805–818.

4. Hull E, Hafkesbring E. "Toxic" post partal heart disease. N Orleans Med Surg J. 1937. 89:550–557.

5. Brown CS, Bertolet BD. Peripartum cardiomyopathy: a comprehensive review. Am J Obstet Gynecol. 1998. 178:409–414.

6. Cunningham FG, Pritchard JA, Hankins GD, Anderson PL, Lucas MJ, Armstrong KF. Peripartum heart failure: idiopathic cardiomyopathy or compounding cardiovascular events? Obstet Gynecol. 1986. 67:157–168.

7. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med. 1963. 111:651–655.

8. van Hoeven KH, Kitsis RN, Katz SD, Factor SM. Peripartum versus idiopathic dilated cardiomyopathy in young women-a comparison of clinical, pathologic and prognostic features. Int J Cardiol. 1993. 40:57–65.

9. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J. 1995. 130:860–870.

10. Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol. 1994. 74:474–477.

11. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendation and review. JAMA. 2000. 283:1183–1188.

12. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol. 1999. 94:311–316.

13. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000. 342:1077–1084.

14. Homans DC. Peripartum cardiomyopathy. N Engl J Med. 1985. 312:1432–1437.

15. Ritchie C. Clinical contribution to the pathology, diagnosis, and treatment of certain chronic diseases of the heart. Edinb Med Surg J. 1849. 2:333–342.

16. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy especially the puerperium. Am J Med Sci. 1937. 19:185–199.

17. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997. 176:182–188.

18. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct. 1995. 25:118–123.

19. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005. 80:1602–1606.

20. Sanderson JE, Adesanya CO, Anjorin FI, Parry EH. Postpartum cardiac failure-heart failure due to volume overload? Am Heart J. 1979. 97:613–621.

21. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006. 368:687–693.

22. Heider AL, Kuller JA, Strauss RA, Wells SR. Peripartum cardiomyopathy: a review of the literature. Obstet Gynecol Surv. 1999. 54:526–531.

23. Ro A, Frishman WH. Peripartum cardiomyopathy. Cardiol Rev. 2006. 14:35–42.

24. Burch GE, McDonald CD, Walsh JJ. The effect of prolonged bed rest on postpartal cardiomyopathy. Am Heart J. 1971. 81:186–201.

25. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughaman KL. Peripartum myocarditis and cardiomyopathy. Circulation. 1990. 81:922–928.

26. Lee W. Clinical management of gravid women with peripartum cardiomyopathy. Obstet Gynecol Clin North Am. 1991. 18:257–271.

27. Ford RF, Barton JR, O'brien JM, Hollingsworth PW. Demographics, management, and outcome of peripartum cardiomyopathy in a community hospital. Am J Obstet Gynecol. 2000. 182:1036–1038.

28. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol. 2003. 102:1326–1331.

29. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005. 111:2050–2055.

30. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sarelil P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/Apo-1. J Am Coll Cardiol. 2000. 35:701–705.

31. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006. 27:441–446.

32. Velickovic IA, Leicht CH. Peripartum cardiomyopathy and cesarean section: report of two cases and literature review. Arch Gynecol Obstet. 2004. 270:307–310.

33. Diao M, Diop IB, Kane A, Camara S, Kane A, Sarr M, et al. Electrocardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss. 2004. 97:25–30.

34. Fett JD, Carraway RD, Dowell DL, King ME, Pierre R. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol. 2002. 186:1005–1010.

35. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006. 152:509–513.

36. Zangrillo A, Landoni G, Pappalardo F, Oppizzi M, Torri G. Different anesthesiological management in two high risk pregnant women with heart failure undergoing emergency cesarean section. Minerva Anestesiol. 2005. 71:227–236.

37. Kaufman I, Bondy R, Benjamin A. Peripartum cardiomyopathy and thromboembolism; anesthetic management and clinical course of an obese, diabetic patient. Can J Anaesth. 2003. 50:161–165.

38. Ravikishore AG, Kaul UA, Sethi KK, Khalilullah M. Peripartum cardiomyopathy: prognostic variables at initial evaluation. Int J Cardiol. 1991. 32:377–380.

39. Yahagi N, Kumon K, Nakatani T, Ishikawa T, Tanigami H, Eishi K, et al. Peripartum cardiomyopathy and tachycardia followed by multiple organ failure. Anesth Analg. 1994. 79:581–582.

40. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg. 2004. 98:822–824.

41. Malinow AM, Butterworth JF, Johnson MD, Safon L, Rein M, Hartwell B, et al. Peripartum cardiomyopathy presenting at cesarean delivery. Anesthesiology. 1985. 63:545–547.

42. Shnaider R, Ezri T, Szmuk P, Larson S, Warters RD, Katz H. Combined spinal-epidural anesthesia for cesarean section in a patient with peripartum dilated cardiomyopathy. Can J Anaesth. 2001. 48:681–683.

43. Avila WS, de Carvalho MEC, Tschaen CK, Rossi EG, Grinberg M, Mady C, et al. Pregnancy and peripartum cardiomyopathy. A comparative and prospective study. Arq Bras Cardiol. 2002. 79:484–493.

44. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001. 344:1567–1571.

45. O'Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986. 8:52–56.

46. Melvin KR, Richardson PJ, Olsen EG, Daly K, Jackson G. Peripartum cardiomyopathy due to myocarditis. N Engl J Med. 1982. 307:731–734.

47. Sutton MS, Cole P, Plappert M, Saltzman D, Goldhaber S. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J. 1991. 121:1776–1778.

48. Cénac A, Gaultier Y, Devillechabrolle A, Moulias R. Enterovirus infection in peripartum cardiomyopathy. Lancet. 1988. 2:968–969.

49. Cénac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol. 1992. 36:57–59.

50. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002. 23:301–324.

51. Podewski EK, Hilfiker A, Kaminski K, Quint A, Apuya D, Podewski E, et al. Stat3 protects female hearts from postpartum cardiomyopathy in the mouse: the potential role of prolactin (Abstract P2178). 2004. Munich: European Society of Cardiology Meeting.

52. Hayakawa Y, Chandra M, Mial W, Shirani J, Brown JH, Dorn GW, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003. 108:3036–3041.

53. Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol. 2002. 86:311–316.

54. Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000. 140:785–791.

55. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology molecular pathology. Circulation. 2004. 109:1250–1258.

56. Borczuk AC, van Hoeven KH, Factor SM. Review and hypothesis: the eosinophil and peripartum heart disease (myocarditis and coronary artery dissection)-coincidence or pathogenetic significance? Cardiovasc Res. 1997. 33:527–532.

57. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002. 53:822–830.

58. Bültmann BD, Klingel K, Näbauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005. 193:363–365.

59. Zimmermann O, Kochs M, Zwaka TP, Kaya Z, Lepper PM, Bienek-Ziolkowski M, et al. Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. Int J Cardiol. 2005. 104:92–100.

60. Sakakibara S, Sekiguchi M, Konno S, Kusumoto M. Idiopathic postpartum cardiomyopathy: report of a case with special reference to its ultrastructural changes in the myocardium as studies by endomyocardial biopsy. Am Heart J. 1970. 80:385–395.

61. Nelson JL. Pregnancy, persistent microchimerism and autoimmune disease. J Am Med Womens Assoc. 1998. 53:31–32. 47

62. McMullan MR, Moore CK, O'Connell JB. Diagnosis and management of peripartum cardiomyopathy. Hosp Pract (Off Ed). 1993. 28:89–92. 96–98. 103–104.

63. Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom C, Arif G, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005. 150:263–269.

64. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J. 2003. 24:761–781.

65. Phillips SD, Warnes CA. Peripartum cardiomyopathy: current therapeutic perspectives. Curr Treat Options Cardiovasc Med. 2004. 6:481–488.

66. Levander OA, Beck MA. Selenium and viral virulence. Br Med Bull. 1999. 55:528–533.

67. Saito Y, Hashimoto T, Sasaki M, Hanaoka S, Sugai K. Effect of selenium deficiency on cardiac function of individuals with severe disabilities under long-term tube feeding. Dev Med Child Neurol. 1998. 40:743–748.

68. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol. 1993. 168:493–495.

69. Ray P, Murphy GJ, Shutt LE. Recognition and management of maternal cardiac disease in pregnancy. Br J Anaesth. 2004. 93:428–439.

70. Coulson CC, Thorp JM, Mayer DC, Cefalo RC. Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol. 1996. 87:610–612.

71. Cénac A, Djibo A, Chaigneau C, Velmans N, Orfila J. Are anti-Chlamydia pneumoniae antibodies prognosis indicators for peripartum cardiomyopathy? J Cardiovasc Risk. 2003. 10:195–199.

72. Sundstrom JB, Fett JD, Carraway RD, Ansari AA. Is peripartum cardiomyopathy an organ specific autoimmune disease? Autoimmun Rev. 2002. 1:73–77.

73. Dickfeld T, Gagliardi JP, Marcos J, Russell SD. Peripartum cardiomyopathy presenting as an acute myocardial infarction. Mayo Clin Proc. 2002. 77:500–501.

74. Box LC, Hanak V, Arciniegas JG. Dual coronary emboli in peripartum cardiomyopathy. Tex Heart Inst J. 2004. 31:442–444.

75. McIndoe AK, Hammond EJ, Babington PC. Peripartum cardiomyopathy presenting as a cardiac arrest at induction of anaesthesia for emergency caesarean section. Br J Anaesth. 1995. 75:97–101.

76. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol. 1997. 176:189–195.

77. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995. 333:269–275.

78. Aziz TM, Burgess MI, Acladious NN, Campbell CS, Rahman AN, Yonan N, et al. Heart transplantation for peripartum cardiomyopathy: a report of three cases and a literature review. Cardiovasc Surg. 1999. 7:565–567.

79. Okutomi T, Saito M, Amano K, Fukuoka K, Hoka S. Labour analgesia guided by echocardiography in a parturient with primary dilated cardiomyopathy. Can J Anaesth. 2005. 52:622–625.

80. Barfield WE. Wolff-Parkinson-White syndrome and peripartum cardiomyopathy in a pregnant patient. Am J Obstet Gynecol. 1982. 144:989–990.

81. Ardehali H, Kasper EK, Baughman KL. Peripartum cardiomyopathy. Minerva Cardioangiol. 2003. 51:41–48.

82. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995. 130:871–876.

83. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999. 341:709–717.

84. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991. 325:303–310.

85. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodepine Survival Evaluation Study Group. N Engl J Med. 1996. 335:1107–1114.

86. Mohler ER, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol. 1997. 30:35–41.

87. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996. 334:1349–1355.

88. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004. 126:627S–644S.

89. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ, MacGowan GA, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999. 34:177–180.

90. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001. 103:2254–2259.

91. Veille JC, Zaccaro D. Peripartum cardiomyopathy: summary of an international survey on peripartum cardiomyopathy. Am J Obstet Gynecol. 1999. 181:315–319.

92. Aravot DJ, Banner NR, Dhalla N, Fitzgerald M, Khaghani A, Radley-Smith R, et al. Heart transplantation for peripartum cardiomyopathy. Lancet. 1987. 2:1024.

93. Lewis R, Mabie WC, Burlew B, Sibai BM. Biventricular assist device as a bridge to cardiac transplantation in the treatment of peripartum cardiomyopathy. South Med J. 1997. 90:955–958.

94. George LM, Gatt SP, Lowe S. Peripartum cardiomyopathy: four case histories and a commentary on anaesthetic management. Anaesth Intensive Care. 1997. 25:292–296.

95. Gambling DR, Flanagan ML, Huckell VF, Lucas SB, Kim JH. Anaesthetic management and non-invasive monitoring for cesarean section in a patient with cardiomyopathy. Can J Anaesth. 1987. 34:505–508.

96. McCarroll CP, Paxton LD, Elliott P, Wilson DB. Use of remifentanil in a patient with peripartum cardiomyopathy requiring Caesarean section. Br J Anaesth. 2001. 86:135–138.

97. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000. 343:246–253.

98. Mellor DJ, Bodenham A. Infiltration anaesthesia in the management of Caesarean section in a patient with peripartum cardiomyopathy. Anaesthesia. 1996. 51:409.

99. Ceci O, Berardesca C, Caradonna F, Corsano P, Guglielmi R, Nappi L. Recurrent peripartum cardiomyopathy. Eur J Obstet Gynecol Reprod Biol. 1998. 76:29–30.